US Senator Durbin criticizes delayed FDA e-cigarette review.

May.23.2022
US Senator Dick Durbin criticized the FDA for delaying the public health review of tobacco products before electronic cigarettes hit the market.

During a speech in the Senate, US Senator Dick Durbin criticized the FDA for delaying completion of the public health review of tobacco product applications (PMTA) prior to the launch of electronic cigarettes. The deadline for the FDA to complete review of e-cigarette applications was over eight months ago on September 9th, 2021.

 

The FDA announced on June 13th that it has filed the latest update on its review of electronic cigarette applications, stating that the review process will not be completed until July 2023. Products currently under review may still be available for sale.

 

These companies are saturating the market with addictive devices. Companies like Juul, which are partially owned by tobacco companies, understand that they are marketing their products to children," said Durbin during a press conference in his office. "For years, these products haven't been authorized by law. Who should regulate them? The FDA, but currently, there is no regulation.

 

In March of this year, Senator Durbin and 14 of his colleagues wrote a bipartisan letter calling on the FDA to immediately complete its review of e-cigarettes and reject any applications, particularly those with flavors marketed to children, that do not prove to be beneficial for public health. The letter also urged the removal of all unapproved e-cigarettes from the market.

 

Senator Durbin stated, "I urge the FDA to immediately put an end to their enforcement discretionary power and remove all unauthorized e-cigarettes from the market. Let's not let Juul and other tobacco companies continue to endanger our children for another day. Let's not cower in front of high-paid tobacco lawyers again.

 

Source: Tobacco Reporter

 

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Altria Reports Full-Year 2025 Results: Revenue Down 3.1%, Cigarette Volumes Slide 10% as NJOY Takes Impairment Hit
Altria Reports Full-Year 2025 Results: Revenue Down 3.1%, Cigarette Volumes Slide 10% as NJOY Takes Impairment Hit
Altria has released its full-year 2025 results, reporting full-year net revenues of $23.279 billion, down 3.1% year over year. Domestic cigarette shipment volume fell 10% for the year. on! nicotine pouches reached a 7.7% share of the U.S. oral tobacco category in the fourth quarter. NJOY posted $21 million in net revenues in Q4, while full-year net revenues were negative $13 million (mainly due to returns and related factors).
Jan.30 by 2FIRSTS.ai
Before the Boom:  Why Manufacturing Is Becoming the Deciding Factor in U.S. Nicotine Pouches — An Interview with Rena World
Before the Boom: Why Manufacturing Is Becoming the Deciding Factor in U.S. Nicotine Pouches — An Interview with Rena World
As the U.S. nicotine pouch market moves toward regulatory clarity and rapid growth, attention is shifting from demand to execution. In an interview with 2Firsts, U.S.-based manufacturer Rena explains why manufacturing capacity, quality systems, and compliance readiness are becoming decisive factors before the market fully takes off.
Jan.19
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International (PMI) said its U.S.-related investments have topped $20 billion since 2022, when it entered the U.S. market through its roughly $19 billion acquisition of Swedish Match. The company also said it plans to launch its heated tobacco product IQOS ILUMA in the United States pending authorization from the U.S. Food and Drug Administration (FDA).
Jan.16 by 2FIRSTS.ai
22nd Century Positions VLN® Cigarettes for Growth as FDA Considers 0.7 mg/g Nicotine Cap
22nd Century Positions VLN® Cigarettes for Growth as FDA Considers 0.7 mg/g Nicotine Cap
22nd Century Group (Nasdaq: XXII) reported early commercial momentum for its FDA-authorized VLN® very low nicotine cigarettes, distributing approximately 8,800 cartons across 1,700 new U.S. retail outlets in the fourth quarter of 2025, while forecasting expansion to more than 5,000 retail points in 2026.
Business
Feb.24
New York directs Tax and Finance to build “Vapor Products” registry; products not listed deemed illegal
New York directs Tax and Finance to build “Vapor Products” registry; products not listed deemed illegal
New York Gov. Kathy Hochul says the state will crack down on illegal flavored vapes by creating a registry identifying which vapor products may be legally sold. The governor directed the state Department of Taxation and Finance to establish a “Vapor Products” registry, with products not on the list treated as illegal.
Jan.20 by 2FIRSTS.ai
Fourth Circuit weighs federal preemption challenge to North Carolina’s vape sales restrictions
Fourth Circuit weighs federal preemption challenge to North Carolina’s vape sales restrictions
Vape manufacturers and sellers urged the U.S. Court of Appeals for the Fourth Circuit to find that the federal Food, Drug, and Cosmetic Act (FDCA) preempts North Carolina’s new law restricting the sale of certain e-cigarette/ENDS products.
Feb.03 by 2FIRSTS.ai